


LISTING OF THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1.-13. **(Cancelled)**

14. **(Previously Presented)** A method for treating a subject for glaucoma, comprising administering a therapeutically effective amount of a deprenyl compound to a subject, wherein the deprenyl compound is represented by the structure:



in which

R₁ is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;

R₂ is hydrogen or alkyl;


R₃ is a bond or methylene; and

R₄ is aryl or aralkyl; or

R₂ and R₄-R₃ are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

15. **(Previously Presented)** A method for treating a subject for glaucoma, comprising administering a therapeutically effective amount of a deprenyl compound to a subject, wherein the deprenyl compound is represented by the structure:



in which

R₂ is hydrogen or alkyl;

R₃ is a bond or methylene; and


R_4 is aryl or aralkyl; or

R_2 and R_4 - R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group; and

R_5 is alkylene, alkenylene, alkynylene and alkoxylenes;

and pharmaceutically acceptable salts thereof.

16. **(Previously Presented)** A method for treating a subject for glaucoma, comprising administering a therapeutically effective amount of a deprenyl compound to a subject, wherein the deprenyl compound is represented by the structure:



in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxy carbonyl, or aryloxy carbonyl;

A is a substituent independently selected for each occurrence from the group consisting of halogen, hydroxyl, alkyl, alkoxy, cyano, nitro, amino, carboxyl, $-CF_3$, or azido;

n is 0 or an integer from 1 to 5;

and pharmaceutically acceptable salts thereof.

17.-20. **(Cancelled)**

21. **(Previously Presented)** The method of claim 14, wherein said therapeutically effective amount of a deprenyl compounds is administered with a pharmaceutically acceptable carrier.

22. **(Previously Presented)** The method of claim 21, wherein said pharmaceutically acceptable carrier has a pH of between about 3 and about 5.

23. **(Previously Presented)** The method of claim 22, wherein said pharmaceutically acceptable carrier is an alcohol or aqueous alcohol solution.

24. **(Previously Presented)** The method of claim 21, wherein said pharmaceutically acceptable carrier is suitable for ophthalmic administration.
25. **(Previously Presented)** The method of claim 14, wherein said subject is a human.
26. **(Previously Presented)** The method of claim 15, wherein said therapeutically effective amount of a deprenyl compounds is administered with a pharmaceutically acceptable carrier.
27. **(Previously Presented)** The method of claim 26, wherein said pharmaceutically acceptable carrier has a pH of between about 3 and about 5.
28. **(Previously Presented)** The method of claim 26, wherein said pharmaceutically acceptable carrier is an alcohol or aqueous alcohol solution.
29. **(Previously Presented)** The method of claim 28, wherein said pharmaceutically acceptable carrier is suitable for ophthalmic administration.
30. **(Previously Presented)** The method of claim 15, wherein said subject is a human.
31. **(Previously Presented)** The method of claim 16, wherein said therapeutically effective amount of a deprenyl compounds is administered with a pharmaceutically acceptable carrier.
32. **(Previously Presented)** The method of claim 31, wherein said pharmaceutically acceptable carrier has a pH of between about 3 and about 5.
33. **(Previously Presented)** The method of claim 31, wherein said pharmaceutically acceptable carrier is an alcohol or aqueous alcohol solution.

34. **(Previously Presented)** The method of claim 31, wherein said pharmaceutically acceptable carrier is suitable for ophthalmic administration.
35. **(Previously Presented)** The method of claim 16, wherein said subject is a human.